Summary of Varex Imaging (VREX) Conference Call Company Overview - Varex Imaging is a market leader in imaging components for x-ray based imaging systems, primarily in the medical sector, which constitutes approximately 78-80% of its business [2][3][4]. Core Value Proposition - Varex's competitive advantage lies in its significant investment in innovation, having invested over $1 billion in foundational technologies over the past 20 years, which most OEMs lack [3][4]. - The company employs around 500 people in x-ray product development and holds approximately 600 patents, allowing it to provide bespoke components that help OEMs bring products to market faster [4][5]. Market Trends - The trend in the industry is shifting towards outsourcing rather than insourcing, with Varex working with a wide range of OEMs, including emerging players in markets like India and China [6][7][8]. - The company identifies future winners among OEMs and partners with them, which has been a successful strategy over the years [6][7]. Recent Financial Performance - Varex reported strong fiscal 2Q results, exceeding consensus on revenue, gross margin, and EPS, with a recovery in demand following a period of channel inventory adjustments [10][12]. - The company noted that the audit situation in Chinese hospitals and destocking issues had improved, leading to solid order coverage [12][13]. Tariff Impact and Mitigation Strategies - The tariff situation has been turbulent but is moving in a positive direction, with current tariffs at about 55% for input materials [16][17]. - Varex is implementing several mitigation strategies, including passing on input costs to customers, diversifying its supply chain, and regionalizing manufacturing to enhance resilience [20][21][36]. Manufacturing Developments - Varex is progressing with two factories in India: one for detectors expected to start shipping in 3-4 months, and another for tubes, which is 12-15 months away from production [31][32]. Customer Relationships - Canon remains Varex's top customer, contributing 17-18% of annual revenues, with a stable relationship focused on ongoing R&D projects [51][53]. - The company has observed a healthy demand for its products, with a significant installed base ensuring continued orders for replacement components [25][54]. End Market Dynamics - The medical segment has shown stability, with channel inventory returning to normal operating conditions [47][49]. - In the industrial segment, Varex has seen faster growth compared to medical, driven by demand in global security and cargo inspection markets [60][61]. Direct-to-Customer Opportunities - Varex's direct-to-customer industrial inspection business has shown promising growth, with significant orders in the cargo inspection systems space, which is a billion-dollar addressable market [62][63]. Competitive Landscape - Varex differentiates itself through vertical integration, being one of only two companies globally with this capability, which enhances its innovation and product tailoring [63][64]. Conclusion - Varex Imaging is well-positioned in the imaging components market, leveraging its innovation, strong customer relationships, and strategic responses to market dynamics and challenges, including tariffs and supply chain issues. The company is optimistic about future growth in both medical and industrial sectors.

Company Overview - Nanox Imaging Ltd (NASDAQ: NNOX) is an innovative medical imaging technology company focused on transitioning to preventive health care through affordable medical imaging technologies based on advanced AI and proprietary digital X-ray sources [3][4]. Upcoming Event - Nanox will participate in the Sidoti Small Cap Conference, scheduled for June 11-12, 2025, with management presenting on June 11 at 1:45 PM ET [1]. Technology and Solutions - The company aims to expand the reach of its technology beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, enhancing efficiency in routine medical imaging processes [4]. - Nanox's ecosystem includes several components: - Nanox.ARC, a cost-effective multi-source digital tomosynthesis system - Nanox.AI Ltd., which offers AI-based algorithms to augment routine CT imaging readings - Nanox.CLOUD, a cloud-based platform for data management and imaging analysis - Nanox.MARKETPLACE, a decentralized marketplace for remote access to radiology and cardiology experts [4]. Vision and Goals - The company's vision is to improve early detection and treatment of diseases, ultimately enhancing health outcomes worldwide [4].

Niagara Falls, NY, May 29, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging systems and services, is pleased to announce the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in advanced cardiovascular diagnostics and interventional care. This latest sale highlights the growing demand for Positron’s PET and PET-CT solutions, which combine cutting-edge technology with comprehensive clinical, tech ...

Board Composition Changes - Guerbet's Annual General Meeting voted to reduce the terms of office of directors from six years to four years to comply with the Afep-Medef Code of corporate governance [2][9] - The terms of office for Claire Jouault Massiot, Céline Lamort, Mark Fouquet, Didier Izabel, and Jean-Sebastien Raynaud expired at the Annual General Meeting, and Pascale Auger resigned as a director [3][11] - Two new directors were appointed, Michèle Lesieur and Eric Drapé, while Céline Lamort and Marc Massiot were re-elected, bringing the total number of directors to nine [3][10][11] New Appointments - Michèle Lesieur was appointed as an independent director for a three-year term, bringing extensive experience in the healthcare sector, including leadership roles at Philips and Supersonic Imagine [4][5] - Eric Drapé was appointed as an independent director for a four-year term, with over 35 years of experience in the pharmaceutical industry, including senior positions at Teva Pharmaceuticals and Ipsen Pharma [6][7] Board Structure - The current Board of Directors consists of nine members, including three independent directors: Hugues Lecat, Eric Drapé, and Michèle Lesieur [11][12] - The Board expressed gratitude to outgoing directors for their contributions and welcomed the new appointees [11] Company Overview - Guerbet is a leader in medical imaging, offering a range of pharmaceutical products, medical devices, and digital solutions, with a revenue of €841 million in 2024 [13] - The company invests 9% of its sales in research and development across four centers in France and the United States [13]

Core Insights - Nanox Imaging Ltd reported a net loss of $13.2 million for Q1 2025, an increase from a net loss of $12.2 million in Q1 2024, primarily due to a $1.0 million increase in gross loss [3][8][13] - The company generated revenue of $2.8 million in Q1 2025, up from $2.6 million in Q1 2024, driven by teleradiology services, imaging systems sales, and AI solutions [4][8] - Nanox received FDA 510(k) clearance for its updated Nanox.ARC X system, marking a significant milestone in its mission to enhance access to medical imaging technology [2][8] Financial Performance - The gross loss for Q1 2025 was $3.0 million, with a gross loss margin of 108%, compared to a gross loss of $2.1 million and a margin of 80% in the prior year [5][8] - Non-GAAP gross loss for Q1 2025 was $0.4 million, a decline from a non-GAAP gross profit of $0.6 million in Q1 2024 [14][45] - Revenue from teleradiology services was $2.6 million in Q1 2025, up from $2.4 million in Q1 2024, with a GAAP gross profit margin of approximately 17% [6][8] Operational Highlights - The company has over 60 imaging units in various stages of implementation for commercial, demonstration, and clinical use [2] - Research and development expenses for Q1 2025 were $5.0 million, a slight decrease from $5.2 million in the prior year [10] - Sales and marketing expenses increased to $0.9 million in Q1 2025 from $0.8 million in Q1 2024 [11] Liquidity and Capital Resources - As of March 31, 2025, the company had total cash and cash equivalents of $72.9 million, down from $83.5 million at the end of 2024 [17] - The company experienced negative cash flow from operations of $10.3 million during the reported period [17][38] Future Outlook - Nanox anticipates that the number of clinical, demo, and commercial units will exceed 100 by the end of 2025, assuming stable macroeconomic conditions [16]

30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRIDURHAM, NC and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, will be featured at the American Thoracic Society’s (ATS) 2025 Respiratory Innovation Summit (RIS), taking place May 16–17 at the Marriott Marquis in San Francisco, Cali ...

Core Viewpoint - FONAR Corporation reported its financial results for the third quarter and nine-month period of fiscal 2025, highlighting growth in revenues but a decline in income from operations and net income for the nine-month period compared to the previous year [2][3][7]. Financial Performance - Total Revenues-Net for the quarter ended March 31, 2025, increased by 6% to $27.2 million compared to $25.7 million for the same quarter in 2024 [3][10]. - Total Revenues-Net for the nine-month period ended March 31, 2025, was $77.1 million, slightly up from $76.9 million for the same period in 2024 [3][50]. - Income From Operations for the quarter decreased by 2% to $3.66 million compared to $3.75 million for the same quarter in 2024 [6][10]. - Income From Operations for the nine-month period decreased by 30% to $10.7 million compared to $15.2 million for the same period in 2024 [6][50]. - Net Income for the quarter increased by 24% to $3.1 million compared to $2.5 million for the same quarter in 2024 [7][10]. - Net Income for the nine-month period decreased by 25% to $9.3 million compared to $12.5 million for the same period in 2024 [7][11]. Cost Analysis - Selling, general & administrative costs (SG&A) increased by 5% to $8.0 million for the quarter compared to $7.6 million in the same quarter of 2024 [4][10]. - SG&A costs increased by 11% to $20.1 million for the nine-month period compared to $18.0 million for the same period in 2024 [4][50]. - Total Costs and Expenses for the quarter were $23.5 million, up from $22.0 million in the same quarter of 2024 [5][10]. - Total Costs and Expenses for the nine-month period were $66.4 million compared to $61.7 million for the same period in 2024 [5][50]. Balance Sheet Highlights - Total Cash, Cash Equivalents, and Short-Term Investments decreased by 4% to $54.4 million as of March 31, 2025, compared to $56.5 million at June 30, 2024 [10][12]. - Total Current Assets increased to $141.1 million as of March 31, 2025, compared to $140.3 million at June 30, 2024 [12]. - Total Assets increased to $214.9 million as of March 31, 2025, compared to $214.2 million at June 30, 2024 [12][13]. - Total Current Liabilities decreased to $14.0 million as of March 31, 2025, compared to $17.9 million at June 30, 2024 [12][13]. Operational Achievements - The Health Management Company of America (HMCA) set a new record by completing 54,612 MRI scans in the third quarter of Fiscal 2025, which was 2.8% higher than the previous quarter and 3.4% higher than the same quarter in Fiscal 2024 [16]. - HMCA managed 44 MRI scanners, with plans to add more facilities to expand its network in New York and Florida [16][17]. Shareholder Actions - As of March 31, 2025, FONAR repurchased 373,942 shares at a cost of $6.07 million as part of its stock repurchase plan announced in September 2022 [17].

Core Insights - Hyperfine, Inc. reported its first quarter 2025 financial results and highlighted progress in expanding its business pipeline, particularly in the neurology office setting, while facing longer sales cycles in hospitals [2][4] Business Highlights - The company has made significant advancements in its commercial efforts, focusing on both hospitals and neurology offices, which is expected to diversify its revenue profile starting in the second half of 2025 [2] - Hyperfine completed a reorganization to reduce operating costs and raised $6 million through a registered direct offering, extending its cash runway until the end of 2026 [7] - The company initiated patient enrollment in the NEURO PMR study to evaluate the use of AI-powered portable MRI in neurology offices, with completion expected by the end of Q3 2025 [7] Financial Results - Revenues for Q1 2025 were $2.1 million, down from $3.3 million in Q1 2024 [7] - Gross margin for Q1 2025 was $0.9 million, representing a gross margin of 41.3%, slightly up from 41.1% in Q1 2024 [7] - The net loss for Q1 2025 was $9.4 million, or $0.12 per share, compared to a net loss of $9.8 million, or $0.14 per share, in Q1 2024 [7][16] Financial Guidance - Management expects revenue for the first half of 2025 to be approximately $5 to $6 million and anticipates annual revenue growth of 10% to 20% over 2024 [7] - The projected cash burn for the full year 2025 is approximately $25 to $28 million, indicating a 31% decline at the midpoint compared to 2024 [7]

Group 1 - VAREX IMAGING reported $212.9 million in revenue for the quarter ended March 2025, a year-over-year increase of 3.3% [1] - The EPS for the same period was $0.26, compared to $0.16 a year ago, indicating a significant improvement [1] - The reported revenue exceeded the Zacks Consensus Estimate of $206.83 million by 2.93%, and the EPS surprised by 85.71% against the consensus estimate of $0.14 [1] Group 2 - VAREX IMAGING's Industrial revenues were $59.10 million, slightly below the estimated $59.12 million, reflecting a 3% year-over-year change [4] - Medical revenues reached $153.80 million, surpassing the average estimate of $147.36 million, marking a 3.4% increase year-over-year [4] - Gross profit for Industrial was $20.80 million, exceeding the estimated $19.64 million, while Medical gross profit was $55.90 million, above the estimated $48.61 million [4] Group 3 - VAREX IMAGING shares have returned -6% over the past month, contrasting with the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Varex Imaging (VREX) Q2 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Christopher Belfiore - Director-Investor RelationsSunny Sanyal - President & Chief Executive OfficerShubham Maheshwari - Chief Financial OfficerYoung Li - Senior VP - Equity ResearchShaymus Contorno - Equity Research AssociateBrandon Carney - Senior Research Associate Conference Call Participants Larry Solow - Partner & Managing director - Equity AnalystAlex Hantman - AnalystSaurabh Prasad - Senior Credit Analyst Operat ...